MEGACE Drug Patent Profile

✉ Email this page to a colleague

When do Megace patents expire, and what generic alternatives are available?

Megace is a drug marketed by Bristol Myers Squibb and Endo Operations and is included in three NDAs. There are five patents protecting this drug.

The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Megace

A generic version of MEGACE was approved as megestrol acetate by STRIDES PHARMA on August 8^th, 1988.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for MEGACE?
What are the global sales for MEGACE?
What is Average Wholesale Price for MEGACE?

Summary for MEGACE

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	35
Patent Applications:	4,436
Drug Prices:	Drug price information for MEGACE
DailyMed Link:	MEGACE at DailyMed

Drug patent expirations by year for MEGACE

Recent Clinical Trials for MEGACE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1/Phase 2
Ontario Institute for Cancer Research	Phase 1
Sunnybrook Health Sciences Centre	Phase 1

See all MEGACE clinical trials

US Patents and Regulatory Information for MEGACE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	MEGACE	megestrol acetate	SUSPENSION;ORAL	020264-001	Sep 10, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Endo Operations	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Endo Operations	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Endo Operations	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MEGACE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	MEGACE	megestrol acetate	SUSPENSION;ORAL	020264-001	Sep 10, 1993	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MEGACE

See the table below for patents covering MEGACE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Ireland	77167	Megestrol acetate formulation	⤷ Sign Up
Czech Republic	289620	Orální antineoplastický přípravek na bázi megestrol-acetátu (Oral antineoplastic preparation based on megestrol-acetate)	⤷ Sign Up
Austria	142882		⤷ Sign Up
Hungary	213511	PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION CONTAINING MEGESTROL ACETATE	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for MEGACE

Recent Clinical Trials for MEGACE

Make Better Decisions: Try a trial or see plans & pricing